Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 March 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 3MB, 220 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 100 results:
Author [ Title(Desc)] Type Year
Filters: Author is de Vries, F.  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
A. M. Gallagher, Dedman, D., Padmanabhan, S., Leufkens, H. G. M., and de Vries, F., “The accuracy of date of death recording in the Clinical Practice Research Datalink GOLD database in England compared with the Office for National Statistics death registrations”, Pharmacoepidemiol Drug Saf, 2019.
I. Essers, Stolwijk, C., Boonen, A., De Bruin, M. L., Bazelier, M. T., de Vries, F., and van Tubergen, A., “Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study”, Ann Rheum Dis, vol. 75, pp. 203-9, 2016.
V. Abbing-Karahagopian, Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G., Slattery, J., Alvarez, Y., Miret, M., Gil, M., Oliva, B., Hesse, U., Requena, G., de Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlienger, R. G., de Groot, M. C., Klungel, O. H., van Staa, T. P., van Dijk, L., Egberts, A. C., Gardarsdottir, H., and De Bruin, M. L., “Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications”, Eur J Clin Pharmacol, vol. 70, pp. 849-57, 2014.
C. Klop, Gibson-Smith, D., Elders, P. J., Welsing, P. M., Leufkens, H. G., Harvey, N. C., Bijlsma, J. W., van Staa, T. P., and de Vries, F., “Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010”, Osteoporos Int, vol. 26, pp. 1919-28, 2015.
R. Williams, Kothny, W., Serban, C., Lopez-Leon, S., de Vries, F., and Schlienger, R., “Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: A European multidatabase, noninterventional, postauthorization safety study”, Endocrinol Diabetes Metab, vol. 2, p. e00084, 2019.
S. Abtahi, Burden, A. M., Geusens, P., van den Bergh, J. P., Van Staa, T., and de Vries, F., “The Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population-Based Cohort Study”, J Am Med Dir Assoc, 2019.
B
O. A. Oshagbemi, Franssen, F. M. E., van Kraaij, S., Braeken, D. C. W., Wouters, E. F. M., van der Zee, A. H. Maitlan, Driessen, J. H. M., and de Vries, F., “Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD)”, Copd, pp. 1-8, 2019.
O. A. Oshagbemi, Franssen, F. M. E., Braeken, D. C. W., Henskens, Y., Wouters, E. F. M., van der Zee, A. H. Maitlan, Burden, A. M., and de Vries, F., “Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality”, Pharmacoepidemiol Drug Saf, vol. 27, pp. 1191-1199, 2018.
J. H. Driessen, Henry, R. M., van Onzenoort, H. A., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G., and de Vries, F., “Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis”, Calcif Tissue Int, vol. 97, pp. 104-12, 2015.
V. Abbing-Karahagopian, Kurz, X., de Vries, F., van Staa, T. P., Alvarez, Y., Hesse, U., Hasford, J., Dijk, L., de Abajo, F. J., Weil, J. G., Grimaldi-Bensouda, L., Egberts, A. C., Reynolds, R. F., and Klungel, O. H., “Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project”, Curr Clin Pharmacol, vol. 9, pp. 130-8, 2014.
C
R. Williams, van Staa, T. P., Gallagher, A. M., Hammad, T., Leufkens, H. G. M., and de Vries, F., “Cancer recording in patients with and without type 2 diabetes in the Clinical Practice Research Datalink primary care data and linked hospital admission data: a cohort study”, BMJ Open, vol. 8, p. e020827, 2018.
A. But, De Bruin, M. L., Bazelier, M. T., Hjellvik, V., Andersen, M., Auvinen, A., Starup-Linde, J., Schmidt, M. K., Furu, K., de Vries, F., Karlstad, O., Ekstrom, N., and Haukka, J., “Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study”, Diabetologia, vol. 60, pp. 1691-1703, 2017.
R. Williams, de Vries, F., Kothny, W., Serban, C., Lopez-Leon, S., Chu, C., and Schlienger, R., “Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study”, Diabetes Obes Metab, vol. 19, pp. 1473-1478, 2017.
A. Lalmohamed, Bazelier, M. T., van Staa, T. P., Uitdehaag, B. M., Leufkens, H. G., de Boer, A., and de Vries, F., “Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study”, Eur J Neurol, vol. 19, pp. 1007-14, 2012.
den C. Heijer, Hoebe, C., Driessen, J. H., Wolffs, P., van den Broek, I., Hoenderboom, B., Williams, R., de Vries, F., and Dukers-Muijrers, N., “Chlamydia trachomatis and the Risk of Pelvic Inflammatory Disease, Ectopic Pregnancy, and Female Infertility: A Retrospective Cohort Study Among Primary Care Patients”, Clinical Infectious Diseases, 2019.
R. G. de Jong, Gallagher, A. M., Herrett, E., Masclee, A. A., Janssen-Heijnen, M. L., and de Vries, F., “Comparability of the age and sex distribution of the UK Clinical Practice Research Datalink and the total Dutch population”, Pharmacoepidemiol Drug Saf, vol. 25, pp. 1460-1464, 2016.
F. de Vries, Setakis, E., and van Staa, T. P., “Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes”, Br J Clin Pharmacol, vol. 70, pp. 429-38, 2010.
S. Abtahi, Driessen, J. H. M., Burden, A. M., Souverein, P. C., van den Bergh, J. P., van Staa, T. P., Boonen, A., and de Vries, F., “Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study”, Ann Rheum Dis, 2020.
O. A. Oshagbemi, Franssen, F. M. E., Wouters, E. F. M., van der Zee, A. H. Maitlan, Driessen, J. H. M., de Boer, A., and de Vries, F., “C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPD”, Pulm Pharmacol Ther, p. 101870, 2019.
E
G. Wallace, Judge, A., Prieto-Alhambra, D., de Vries, F., Arden, N. K., and Cooper, C., “The effect of body mass index on the risk of post-operative complications during the 6 months following total hip replacement or total knee replacement surgery”, Osteoarthritis Cartilage, vol. 22, pp. 918-27, 2014.
I. E. Bultink, Harvey, N. C., Lalmohamed, A., Cooper, C., Lems, W. F., van Staa, T. P., and de Vries, F., “Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom”, Osteoporos Int, vol. 25, pp. 1275-83, 2014.
C. Stolwijk, Essers, I., van Tubergen, A., Boonen, A., Bazelier, M. T., De Bruin, M. L., and de Vries, F., “The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study”, Ann Rheum Dis, vol. 74, pp. 1373-8, 2015.
E. M. Curtis, van der Velde, R., Moon, R. J., van den Bergh, J. P., Geusens, P., de Vries, F., van Staa, T. P., Cooper, C., and Harvey, N. C., “Epidemiology of fractures in the United Kingdom 1988-2012: Variation with age, sex, geography, ethnicity and socioeconomic status”, Bone, vol. 87, pp. 19-26, 2016.
C. Klop, van Staa, T. P., Cooper, C., Harvey, N. C., and de Vries, F., “The epidemiology of mortality after fracture in England: variation by age, sex, time, geographic location, and ethnicity”, Osteoporos Int, vol. 28, pp. 161-168, 2017.
R. J. Moon, Harvey, N. C., Curtis, E. M., de Vries, F., Van Staa, T., and Cooper, C., “Ethnic and geographic variations in the epidemiology of childhood fractures in the United Kingdom”, Bone, vol. 85, pp. 9-14, 2016.
C. Huerta, Abbing-Karahagopian, V., Requena, G., Oliva, B., Alvarez, Y., Gardarsdottir, H., Miret, M., Schneider, C., Gil, M., Souverein, P. C., De Bruin, M. L., Slattery, J., de Groot, M. C., Hesse, U., Rottenkolber, M., Schmiedl, S., Montero, D., Bate, A., Ruigomez, A., Garcia-Rodriguez, L. A., Johansson, S., de Vries, F., Schlienger, R. G., Reynolds, R. F., Klungel, O. H., and de Abajo, F. J., “Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project”, Pharmacoepidemiol Drug Saf, vol. 25 Suppl 1, pp. 56-65, 2016.
F
S. Pouwels, Bazelier, M. T., de Boer, A., Weber, W. E., Neef, C. K., Cooper, C., and de Vries, F., “Five-year fracture risk estimation in patients with Parkinson's disease”, Bone, vol. 56, pp. 266-70, 2013.
S. Pouwels, de Boer, A., Javaid, M. K., Hilton-Jones, D., Verschuuren, J., Cooper, C., Leufkens, H. G., and de Vries, F., “Fracture rate in patients with myasthenia gravis: the general practice research database”, Osteoporos Int, vol. 24, pp. 467-76, 2013.
D. Prieto-Alhambra, Javaid, M. K., Judge, A., Maskell, J., Kiran, A., de Vries, F., Cooper, C., and Arden, N. K., “Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use”, Arthritis Rheum, vol. 63, pp. 992-1001, 2011.
F. de Vries, Cooper, A. L., Cockle, S. M., van Staa, T. P., and Cooper, C., “Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates”, Osteoporos Int, vol. 20, pp. 1989-98, 2009.
F. de Vries, Bracke, M., Leufkens, H. G., Lammers, J. W., Cooper, C., and van Staa, T. P., “Fracture risk with intermittent high-dose oral glucocorticoid therapy”, Arthritis Rheum, vol. 56, pp. 208-14, 2007.
G
R. de Jong, Peeters, P., Burden, A. M., De Bruin, M. L., Haak, H. R., Masclee, A. A. M., de Vries, F., and Janssen-Heijnen, M. L. G., “Gastrointestinal cancer incidence in type 2 diabetes mellitus; results from a large population-based cohort study in the UK”, Cancer Epidemiol, vol. 54, pp. 104-111, 2018.
H
B. P. Verhaegh, de Vries, F., Masclee, A. A., Keshavarzian, A., de Boer, A., Souverein, P. C., Pierik, M. J., and Jonkers, D. M., “High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors”, Aliment Pharmacol Ther, vol. 43, pp. 1004-13, 2016.
I
J. T. Nielen, van den Bemt, B. J., Boonen, A., Dagnelie, P. C., Emans, P. J., Veldhorst, N., Lalmohamed, A., van Staa, T. P., and de Vries, F., “Identification of antithrombotic drugs related to total joint replacement using anonymised free-text notes: a search strategy in the Clinical Practice Research Datalink”, BMJ Open, vol. 5, p. e009017, 2015.
A. M. Gallagher, Williams, T., Leufkens, H. G., and de Vries, F., “The Impact of the Choice of Data Source in Record Linkage Studies Estimating Mortality in Venous Thromboembolism”, PLoS One, vol. 11, p. e0148349, 2016.
J. T. H. Nielen, Dagnelie, P. C., Boonen, A., Klungel, O., van den Bemt, B., and de Vries, F., “Impact of the definition of osteoarthritis and of the timing of its onset on the association between type 2 diabetes mellitus and osteoarthritis: Clinical Practice Research Datalink”, Diabetes Res Clin Pract, vol. 148, pp. 240-248, 2019.
M. Schuerch, Gasse, C., Robinson, N. J., Alvarez, Y., Walls, R., Mors, O., Christensen, J., Hesse, U., de Groot, M., Schlienger, R., Reynolds, R., Klungel, O., and de Vries, F., “Impact of varying outcomes and definitions of suicidality on the associations of antiepileptic drugs and suicidality: comparisons from UK Clinical Practice Research Datalink (CPRD) and Danish national registries (DNR)”, Pharmacoepidemiol Drug Saf, vol. 25 Suppl 1, pp. 142-55, 2016.
R. Y. van der Velde, Wyers, C. E., Geusens, P., van den Bergh, J. P. W., de Vries, F., Cooper, C., van de Staa, T. P., and Harvey, N. C., “Incidence of subsequent fractures in the UK between 1990 and 2012 among individuals 50 years or older”, Osteoporos Int, vol. 29, pp. 2469-2475, 2018.
M. Simeonova, de Vries, F., Pouwels, S., Driessen, J. H. M., Leufkens, H. G. M., Cadarette, S. M., and Burden, A. M., “Increased risk of all-cause mortality associated with domperidone use in Parkinson's patients: a population-based cohort study in the UK”, Br J Clin Pharmacol, vol. 84, pp. 2551-2561, 2018.
J. M. Wijnands, van Durme, C. M., Driessen, J. H., Boonen, A., Klop, C., Leufkens, B., Cooper, C., Stehouwer, C. D., and de Vries, F., “Individuals With Type 2 Diabetes Mellitus Are at an Increased Risk of Gout But This Is Not Due to Diabetes: A Population-Based Cohort Study”, Medicine (Baltimore), vol. 94, p. e1358, 2015.
M. E. Goossens, Buntinx, F., Zeegers, M. P., Driessen, J. H., De Bruin, M. L., and de Vries, F., “Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients”, Br J Clin Pharmacol, vol. 80, pp. 1464-72, 2015.
P. J. Peeters, Bazelier, M. T., Leufkens, H. G., Auvinen, A., van Staa, T. P., de Vries, F., and De Bruin, M. L., “Insulin glargine use and breast cancer risk: Associations with cumulative exposure”, Acta Oncol, vol. 55, pp. 851-8, 2016.
L
I. Wilting, de Vries, F., Thio, B. M., Cooper, C., Heerdink, E. R., Leufkens, H. G., Nolen, W. A., Egberts, A. C., and van Staa, T. P., “Lithium use and the risk of fractures”, Bone, vol. 40, pp. 1252-8, 2007.
F. de Vries, Setakis, E., Zhang, B., and van Staa, T. P., “Long-acting {beta}2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD”, Eur Respir J, vol. 36, pp. 494-502, 2010.
J. H. Driessen, van den Bergh, J. P., van Onzenoort, H. A., Henry, R. M., Leufkens, H. G., and de Vries, F., “Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study”, Diabetes Obes Metab, vol. 19, pp. 421-428, 2017.
M
L. Scheepers, Burden, A. M., Arts, I. C. W., Spaetgens, B., Souverein, P., de Vries, F., and Boonen, A., “Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD)”, Rheumatology (Oxford), vol. 57, pp. 1641-1650, 2018.
I. E. M. Bultink, de Vries, F., van Vollenhoven, R. F., and Lalmohamed, A., “Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls”, Rheumatology (Oxford), 2020.
C. Klop, Welsing, P. M., Cooper, C., Harvey, N. C., Elders, P. J., Bijlsma, J. W., Leufkens, H. G., and de Vries, F., “Mortality in British hip fracture patients, 2000-2010: a population-based retrospective cohort study”, Bone, vol. 66, pp. 171-7, 2014.
E. Gieling, de Vries, F., Williams, R., van Onzenoort, H. A. W., de Boer, A., V. Cate, T., Kramers, C., and Burden, A., “Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists”, Int J Clin Pharm, 2019.
O
C. van Durme, Spaetgens, B., Driessen, J., Nielen, J., Sastry, M., Boonen, A., and de Vries, F., “Obstructive sleep apnea and the risk of gout: a population-based case-control study”, Arthritis Res Ther, vol. 22, p. 92, 2020.
[Page last reviewed 4 March 2021]